Results 121 to 130 of about 54,505 (255)

Real‐world progression‐free survival and overall survival in patients with HR+/HER2− advanced breast cancer treated in first‐line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA study

International Journal of Cancer, Volume 159, Issue 1, Page 210-223, 1 July 2026.
What's New? The CDK4/6 inhibitor ribociclib in combination with an endocrine‐based therapy has demonstrated significant progression‐free and overall survival benefits in patients with advanced/metastatic HR+/HER2‐ breast cancer in the pivotal MONALEESA trials.
Peter A. Fasching, Cosima Brucker, Thomas Decker, Anne Engel, Thomas Göhler, Christian Jackisch, Jan Janssen, Andreas Köhler, Kerstin Lüdtke‐Heckenkamp, Diana Lüftner, Frederik Marmé, Marion van Mackelenbergh, Beate Rautenberg, Marcus Schmidt, Rudolf Weide, Pauline Wimberger, Elena Kisseleff, Christina Pfister, Claudia Quiering, Christian Roos, Achim Wöckel   +20 more
wiley   +1 more source

Considerations for the clinical use of teplizumab in stage 2 Type 1 diabetes: A Consensus Statement from the British Society of Paediatric Endocrinology and Diabetes (BSPED) and the Association of British Clinical Diabetologists (ABCD)

Diabetic Medicine, Volume 43, Issue 7, July 2026.
Abstract Introduction In 2025, the Medicines and Healthcare products Regulatory Agency (MHRA) approved the use of teplizumab (a monoclonal anti‐CD3 antibody) to delay progression from Stage 2 to Stage 3 Type 1 diabetes in the UK. Methods To address the need for clear guidance on managing patients eligible for teplizumab therapy, the British Society of ...
Renuka P. Dias, M. Loredana Marcovecchio, Ruben H. Willemsen, Fiona Campbell, Ahmad Ashour, Philip Newland‐Jones, Jennifer Cooper, Parth Narendran, Neil P. Wright   +8 more
wiley   +1 more source

What Is Your Diagnosis? Abnormal WDF Scattergram From the Sysmex XN‐1000V in a Cat

Veterinary Clinical Pathology, EarlyView.
Javier Martínez‐Caro, Laura Chaves‐Falcón, Marta Lemos, Xavier Roura, Luis Bosch, Josep Pastor   +5 more
wiley   +1 more source

Ph‐Negative Acute Lymphoblastic Leukemia in the Older Adults: Biology, Therapeutic Strategies and Unmet Needs

European Journal of Haematology, Volume 117, Issue 1, Page 24-41, July 2026.
ABSTRACT Acute lymphoblastic leukaemia (ALL) in older adults represents a growing clinical challenge, driven by an ageing population, adverse disease biology, and reduced tolerance to intensive chemotherapy. Although pediatric‐inspired regimens have improved outcomes in younger adults with Philadelphia chromosome (Ph)‐negative ALL, survival in older ...
Antonella Bruzzese, Ernesto Vigna, Enrica Antonia Martino, Santino Caserta, Francesco Mendicino, Maria Eugenia Alvaro, Caterina Labanca, Eugenio Lucia, Virginia Olivito, Marco Fiorillo, Nicola Amodio, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

Long‐Term Clinical and Molecular Dynamics in Hypoplastic Myelodysplastic Neoplasia Treated With Immunosuppressive Therapy

European Journal of Haematology, Volume 117, Issue 1, Page 274-278, July 2026.
ABSTRACT Myelodysplastic neoplasia (MDS) comprises heterogeneous clonal hematologic disorders characterized by peripheral cytopenia, bone marrow dysplasia, and a risk of leukemic transformation. A hypoplastic variant (MDS‐h) shares features with aplastic anemia and responds to immunosuppressive therapy (IST).
Hannes Treiber, Christina Ganster, Katayoon Shirneshan, Katharina Rittscher, Elzbieta Brzuszkiewicz, Justin Hasenkamp, Wolfram Jung, Gerald Wulf, Detlef Haase   +8 more
wiley   +1 more source

Targeting the Menin–KMT2A Axis in Acute Leukemia: From Epigenetic Dependency to Clinical Translation

European Journal of Haematology, Volume 117, Issue 1, Page 132-143, July 2026.
ABSTRACT Acute leukemias characterized by a shared epigenetic dependency on the menin–KMT2A axis rely on aberrant HOX‐driven transcriptional programs that sustain leukemic self‐renewal and impair differentiation. This dependency is most evident in KMT2A‐rearranged and NPM1‐mutated acute myeloid leukemia (AML), but also extends to other HOX‐dependent ...
Antonella Bruzzese, Ernesto Vigna, Enrica Antonia Martino, Santino Caserta, Francesco Mendicino, Maria Eugenia Alvaro, Caterina Labanca, Eugenio Lucia, Virginia Olivito, Mamdouh Skafi, Nicola Amodio, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

Mirtazapine-Induced Bicytopenia in a Patient With Multifactorial Delirium: A Case Report. [PDF]

Cureus
Yirdaw BG, Bulcock A.
europepmc   +1 more source

Immune‐Driven Expression in Inclusion Body Myositis With T‐Cell Large Granular Lymphocytic Leukemia

Annals of Clinical and Translational Neurology, Volume 13, Issue 6, Page 1196-1205, June 2026.
ABSTRACT Objectives T‐cell large granular lymphocytic leukemia (T‐LGLL), reported in up to 58% of inclusion body myositis (IBM) patients, is a rare leukemia of cytotoxic or less commonly helper T cells. The range of myopathies in T‐LGLL and the impact of coexisting T‐LGLL in IBM are not well understood. Our objectives are to investigate the spectrum of
Pannathat Soontrapa, Iago Pinal‐Fernandez, Pritikanta Paul, Michael P. Skolka, Margherita Milone, Min Shi, Mithun V. Shah, Maria Casal‐Dominguez, Katherine Pak, Andrew L. Mammen, Teerin Liewluck   +10 more
wiley   +1 more source

Immune-mediated multisystem injury associated with monoclonal gammopathy of clinical significance: a case report. [PDF]

Front Immunol
Jin X, Duan X, Zhang R, Sun Y, Qian M, Li X, Ma D, Li X, Zhang X, Shen M, Zeng X, Xu N, Zhuang J.   +12 more
europepmc   +1 more source

What Is Your Diagnosis? Blood Smear From a Mixed‐Breed Dog

Veterinary Clinical Pathology, EarlyView.
Laura S. Peres, Lina C. Bilhalva, Camila B. E. Mello, Abílio G. Silva, Andrea P. Santos, Stella F. Valle   +5 more
wiley   +1 more source